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Gene therapy holds great promise to treat a variety of human diseases, including diabetes. The 
development of a new gene delivery system called Ultrasound Targeted Microbubble Destruction 
(UTMD) has been developed to enhance in vivo gene delivery using non-viral vectors. A new 
family of cationic lipids called gemini surfactants have been synthesized for their use as gene 
carriers due to their small particle size, increased surface charge, superior surface binding 
capabilities, reduced toxicity, and economic advantages, resulting in their increased safety for in 
vivo application. Gemini surfactants have not been evaluated with UTMD. The purpose of this 
study was to assess their transfection capabilities as microbubble gene carriers.  
First, gemini surfactants 16-3-16 and 16-7NH-16 were assessed and compared to three 
commercially used monovalent cationic lipids: 1) Lipofectamine 2000, 2) Fugene, and 3) 
DOTAP microbubbles. Colloidal stability was assessed using dynamic light scattering to measure 
size and electrophoresis for charge. Gemini surfactants 16-3-16 and 16-7NH-16 displayed a small 





37.74 mV (16-7NH-16) when compared to commercially used monovalent 
cationic lipid Lipofectamine 2000 (size 3.9 µm and charge 
-
6.2 mV). Gemini surfactant 16-7NH-
16 was chosen for further investigation due to its reduced particle size and increased surface 
charge and was investigated for its DNA binding and release capabilities using UTMD though 
gel electrophoresis. Gel electrophoresis analysis determined gemini surfactant 16-7NH-16 was 
capable of fully binding 25 µg of pAMAXA plasmid GFP DNA, but not able to release DNA 
when exposed to ultrasound. Transfection efficiency of gemini surfactant 16-7NH-16 
microbubbles with 25 µg of pAMAXA plasmid GFP DNA was additionally investigated in HEK 
293 (human embryonic kidney cells) and INS-1 832/13 cells (rat insulinoma cells) using UTMD, 
and determined with florescent microscopy. Gemini surfactant 16-7NH-16 microbubbles resulted 
in a 5 % transfection rate and a 90 % death rate in vitro when exposed to UTMD. Commercially 
used monovalent cationic lipid microbubbles exhibited higher transfection rates and lower death 
rates overall in vitro when compared to gemini surfactant 16-7NH-16 microbubbles and exposed 
to UTMD. (Lipofectamine 2000 70 % transfection rate, 5 % death rate, Fugene 70 % transfection 
rate, 5 % death rate, DOTAP 30 % transfection rate, 90 % death rate). Cationic lipid 
microbubbles most influenced in vitro using the UTMD technique for transfection was DOTAP 
in combination with neutral lipids (DOTAP + neutral lipids). Transfection rates of DOTAP + 
neutral lipids increased as ultrasound intensities increased (10 % transfection at intensity 1.5 
W/cm
2 
and 30 % transfection at intensity 2.0 W/cm
2
), demonstrating a direct correlation. In vitro 
gene delivery demonstrated gemini surfactant 16-7NH-16 microbubbles did not significantly 
enhance transfection capabilities when incorporated with the UTMD technique when compared 
to commercially used monovalent cationic lipids. Cationic lipid microbubble most influenced by 
ultrasound was DOTAP + neural lipid microbubbles when compared to all experimental groups 




These results indicate that gemini surfactants, a new family of cationic lipids could not 
significantly enhance cellular transfection rates in vitro with the incorporation of the UTMD 
technique; despite their small particle size, increased surface charge, superior surface binding 
capabilities and economic advantage for in vivo application when compared to commercially 
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Chapter 1 
1.1 Gene Therapy 
Gene therapy is a new therapeutic concept proposed to treat a variety of human diseases. In most 
cases, a disease is a result of the misregulation or expression of a particular gene (Heilbronn et 
al., 2010; Karp et al., 2003). This disruption in gene expression can cause an imbalance in 
biological processes within a cell, resulting in disease. The goal or objective of gene therapy is to 
deliver nucleic acids, either RNA or DNA, into a target cell in order to modify its function 
(Heilbronn et al., 2010; Karp et al. 2003; Robbins et al., 1998). This process involves the 
addition, deletion or the alteration of a specific gene(s) in a target cell (Karp et al., 2003; Robbins 
et al., 1998). Diabetes mellitus, commonly known as diabetes, is a human disease who’s global 
epidemic is on the rise. Gene therapy holds great promise for its medical application as a new 
treatment for this disease. 
1.2  Definition and Etiology of Diabetes Mellitus 
Diabetes is a life altering chronic disease. Diabetes occurs when insulin production from 
pancreatic β-cells is impaired and unable to meet the metabolic demands of peripheral tissues 
(Oliver-Krasinski et al., 2008; Pfeifer et al., 1981; Newsholme et al., 2010). There are two forms 
of diabetes, type 1 and type 2; both forms occur as a result of the impairment in β–cell function 
and mass leading to hyperglycemia (Oliver-Krasinski et al., 2008; Taplin et al., 2008; Castano et 
al., 1990; Ferrannini et al., 1998). 
Type 1 diabetes is classified as an autoimmune disease resulting from the immune-mediated loss 
of insulin-secreting β-cells. The immune system of type 1 diabetics develops auto-antibodies 
which both selectively target and destroy the insulin producing β-cells of the pancreas (Ziegler, et 
al., 2010; Taplin et al., 2008). Type 2 diabetes differs from type 1 as it is not due to the 
misregulation of the immune system, but rather is linked to obesity. Type 2 diabetes is 
characterized by abnormal β-cell function, but not complete insulin deficiency. Type 2 diabetics 
still have the ability to secrete insulin, but there is a malfunctioning in secretion leading 
indiscriminate blood glucose levels (Stock et al., 2004; Stagner et al., 1992; Rahier et al., 2008; 




1.3 Anatomy of the Islets of Langerhans 
The human pancreas is known as both an endocrine and exocrine organ, and holds residence to 
the insulin producing β-cells. The bulk of the pancreas is composed of acinar cells. Acinar cells 
produce enzymes which are secreted and aid during digestion. Scattered among the acinar tissue 
are small clusters of cells known as islets of Langerhans (Marieb, et al., 2007; Samol et al., 
1998). Islet cells are small circular clusters of approximately 1000 cells. Three cell types exist in 
islets, alpha α, beta β and delta δ cells. The orientation of these cells within an islet is important 
for cell signalling and communication to maintain appropriate blood glucose levels (Marieb, et 
al., 2007; Samols et al., 1986; Samol et al., 1998; Unger et al., 1978). The two major hormone 
producing cells of the pancreas are: alpha (α) and beta (β) cells. Alpha cells are responsible for 
producing glucagon and β-cells insulin. It is the β–cells which are responsible for detecting a rise 
in blood glucose levels, and secreting insulin to restore normal blood glucose (Unger et al., 1978; 
Samol et al., 1986; Newsholmen et al., 2010). Glucose not only stimulates insulin secretion 
directly but also stimulates the production of free fatty acids, amino acids, and glucagon like 
peptide -1 (Jensen, et al., 2008). The β-cells of the pancreas are entwined within a delicate 
microvasculature to enable accurate detection of any rise in blood glucose levels (Brunicardi et 
al., 1996; Orci et al., 1975). A supportive extracellular matrix surrounds these cells which directly 
impacts β-cell function, survival and replication (Halban, et al., 2010; Bonner-Weir et al., 1994; 
Bonner-Weir et al., 2000). The β-cells of the pancreas require close coordination, tight control 
and tremendous communication from surrounding cells such as α and δ cells, to sustain adequate 
control to maintain normal glycaemic conditions (Figure 1) (Marieb, et al., 2007; Samols et al., 







Figure 1: Illustration of the human pancreas including islets of Langerhans:
describes the location of the human pancreas, including the islets of Langerhans structure and 
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the exocrine tissue are pancreatic islets, also known as the islets of Langerhans (indicated by the 
blue box). Islets of Langerhans are tiny cell clusters of approximately 1000 cells which produce 
pancreatic hormones. The three main hormone producing cells of an islet are 
(indicated by the red box). α-cells produce the hormone glucagon and prevent hypoglycem
cells produce the hormone insulin preventing hyperglycemia. Islets of Langerhans are highly 
vascularized cellular structures to allow tight control over the rising and lowering of blood 
glucose levels. Marieb, E., (2007). Anatomy & Physiology, sevent
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1.4 Mechanism of Insulin Secretion 
The absolute mechanism and regulation of insulin secretion from pancreatic β-cells is not 
completely understood; although, studies have well established that insulin secretion from β-cells 
occurs in a biphasic fashion in response to a rise in blood glucose (Gembal, et al., 1992; Sato et 
al., 1992; Wang et al., 2009; Hou et al., 2009; Straub et al., 2002). Pancreatic β-cells have the 
capacity to sense a rise in blood glucose levels and produce insulin through several insulin 
secreting pathways. The most intensively investigated pathway is the glucose stimulated pathway 
of insulin secretion (MacDonald et al., 2005; MacDonald et al., 1995, MacDonald et al., 1993; 
Ronnebaum et al., 2005; Ronnebaum et al., 2006).  
The metabolism of glucose plays a key role in regulating insulin release. As glucose levels in the 
blood begin to raise after a meal, a cascade of events occur resulting in insulin secretion (Mears 
et al., 2004; Henquin et al., 2009; Newsholme et al., 2010). Glucose from the blood enters the 
islet cell microcirculation, here pancreatic β-cells respond to increasing extracellular glucose 
levels in a biphasic pattern. The first phase lasts approximately ten minutes and results in a quick 
burst or spike in insulin secretion that declines rapidly after ten minutes. The second phase of 
insulin secretion consists of a steady, slow increase until reaching a plateau after approximately 
thirty minutes (Mears et al 2004; Straub et al., 2002; Wang et al., 2009; Nesher et al., 2002). 
 
1.5 ATP-Sensitive Potassium Channel (K+ATP) Dependent Pathway 
The intracellular mechanism of insulin secretion in response to glucose involves several steps. 
First, glucose enters the β-cell through the glucose transporter 2 (GLUT 2), and initiates 
glycolysis. The end product of glycolysis is the production of two pyruvate molecules, NADH 
and ATP (MacDonald et al., 2005; MacDonald et al., 1995; Henquin et al., 2009; Newsholme et 
al., 2010). As ATP molecules are produced they bind to the KATP channel leading to a rise in the 




channel and the depolarization of the plasma cell membrane (Jacobson et al., 2007; Jitrapakdee et 
al., 2010; Jensen et al., 2008; MacDonald et al., 1995). The depolarization of the β-cell plasma 
membrane results in the activation of the voltage-gated L-type Ca
2+
 channels that causes an 
influx of Ca
2+
 into the cytosol. As Ca
2+
 concentrations increase inside the cell, it signals the 
exocytosis of the immediately releasable pool (IRP) of insulin granules (Henquin et al., 2009; 
MacDonald et al., 2005; Mears et al., 2004; Wang et al., 2009; Jitrapakdee et al., 2010). This first 
acute phase of insulin secretion is known as the KATP channel dependent pathway and its role has 
















Figure 2: Glucose-Stimulated Pathway of Insulin Secretion:
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acid molecules. Pyruvate enters the mitochondrion where it is decarboxylated producing the rapid 
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1.1 ATP-Sensitive Potassium Channel (K+ATP) Independent Pathway 
The idea of another possible pathway involved in insulin secretion has been determined (Pantel et 
al., 1988; Wiederkehr et al., 2009, Henquin et al., 2009). This pathway is known as the KATP 
channel independent pathway and is the result of the second or more sustained phase of the 
biphasic pattern during insulin secretion (Gembal, et al., 1992; Sato et al., 1992). The 
identification of a second pathway was determined through two independent studies. The first 
study investigated insulin secretion by applying sulfonylureas drugs to β-cells. Sulfonyluras 
mimic glucose stimulation by acting directing on membrane potential and Ca
2+
 influx, by closing 
the KATP channels independently of changes in metabolism. In this study, β-cells were bathed in 
high concentrations of glucose at 15 mmol/L, which induced a higher rate of insulin secretion 
when compared to 10 mmol/l and 5 µmol/l of the sulfonylureas drug tolbutamide. It was 
therefore proposed that non-electrical effects of glucose amplify insulin secretion (Henquin, et 
al., 1998; Henquin et al., 2000). A second study determined glucose is able to increase insulin 
secretion in the presence of sulfonylurea concentrations sufficient to close all KATP channels in β-
cells, also leading to the same conclusion that glucose is acting on other targets resulting in 
insulin secretion (Henquin et al., 2009; Henquin et al., 2000; Gembal, et al., 1992; Sato et al., 
1992). Two more studies investigated this hypothesis and demonstrated that glucose can increase 
insulin secretion in the presence of diazoxide. Diazoxide acts as a clamp to hold open the 
potassium channels preventing the influx of Ca
2+
. This effect demonstrated the important role 
metabolism plays during insulin secretion and required to elevate concentrations of Ca
2+
. This 
pathway of insulin secretion has been termed the “metabolic amplifying pathway” (Nenquin et 
al., 2004; Henquin et al., 2000; Henquin 2003; Hellman et al., 1994; Ashcroft et al., 1989;  
Preentki et al., 1987; Cook et al., 1984; Dean et al., 1970). This has lead to its investigation to 
fully understand the mechanisms of insulin secretion at the level of metabolism. 
When describing the first phase of insulin secretion, the end product of glycolsyis is pyruvate in 
β-cells. During metabolism, pyruvate is shuttled from the cytosol of the cell into the mitochondria 




pyruvate carboxylse (PC). Here, pyruvate is shuttled at an equal magnitude and is either 
converted into acetyl-coenzyme A or oxaloacetate. It is these two substrates which are the 
beginning of the anaplerotic pathway resulting in new intermediate metabolites into the TCA 
cycle (Jensen, M.,et al., 2008; Henquin et al., 2003; Maechler et al., 1997). Anabolic pathways 
lead to the production of more complex compounds that are generated from simple starting 
molecules (Karp et al., 2003). After the initial breakdown of pyruvate, three possible pyruvate 
cycling pathways are introduced, pyruvate/malate, pyruvate/citrate, and the pyruvate/isocitrate 
cycle (Jensen, M.,et al., 2008; Joseph et al., 2006; Lue et al., 2002, MacDonald et al., 1995; 
Ogawa et al., 1995; Ronnebaum et al., 2006).  
 
The first possible pathway is termed the pyruvate/malate pathway. This pathway begins by the 
generation of oxaloacetate from the pyruvate enzyme PC. This pathway involves the conversion 
of oxaloacetate to malate by the mitochondrial malate dehydrogenase enzyme. Once converted, 
malate is exported from the mitochondrion by the dicarboxylate malate carrier also known as 
DIC. Once present inside the cytosol, malate is then converted back to pyruvate by the malic 
enzyme resulting in the generation of NADPH, and shuttled back into the mitochondrion for 
further pyruvate cycling (Jensen et al., 2008; MacDonald et al., 1995; Henquin et al., 2003; 
Maechler et al., 1997) (Figure 3). 
 
The second possible pathway is the pyruvate/citrate pathway, and involves the conversion of 
oxaloacetate to citrate. Citrate can follow two paths, either moved outside of the mitochondria by 
the citrate/isocitrate carrier (CIC), or is further broken down to form isocitrate. If citrate is 
shuttled outside the mitochondria into the cytosol, it is cleaved to form oxaloacetate or acetyl-
CoA by the ATP-citrate lyase (CL) enzyme. This cleavage can result in the returning of pyruvate 
back into the mitochondria by the malic enzyme generating more NADPH (Jensen et al., 2008; 
Joseph et al., 2006; Lue et al., 2002, MacDonald et al., 1995; Ogawa et al., 1995; Ronnebaum et 





The last possible pathway is the pyruvate/isocitrate pathway, and involves the export of citrate 
and isocitrate from the mitochondria to the cytosol of the cell through the CIC carrier. Isocitrate 
then serves as a substrate for the NADP
+
-dependent isocitrate dehydrogenase (ICDc) generating 
NADPH and 2-oxoglutarate which can re-enter the TCA cycle or can be converted into α-
ketoglutarate and later producing glutamate which has been proposed to be an additive factor in 
the metabolic amplifying pathway (Figure 3) (Newsholme, et al. 2010; Fallon et al., 2008; 
Jensen, M.,et al., 2008 Joseph et al., 2006; Lue et al., 2002, MacDonald et al., 1995; Ogawa et al., 
1995; Ronnebaum et al., 2006).   
 
Subsequently, glucose metabolism within the mitochondria generates metabolic coupling factors 
ultimately involved in the signaling for insulin secretion (Newsholme, et al. 2010; Henquin et al., 


























Figure 3: ATP-sensitive potassium channel (K
illustrates the TCA cycle and three putative pyruvate cycling pathways which are considered to 
augment insulin secretion via the production of cytosolic NADPH. Reference: MacDonald, 2002, 
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2.1 Prevention & Treatment Strategies for Diabetes 
 
2.2  Prevention   
Type 2 diabetes makes up 90-95% of all diabetic cases. Several studies have provided strong 
correlation between the occurrence of type 2 diabetes and obesity, lack of exercise, an unhealthy 
life style, poverty and a low education background (Creatore et al., 2010; Rahier et al., 2008; 
Colom et al., 2010). These correlative studies, suggest that type 2 diabetes can be prevented or 
even cured by taking on a healthy lifestyle. However, for a minority (approximately 5%) of the 
type 2 diabetics, referred to as maturity onset diabetes of the young (MODY), a change in life 
style will not alter anything as this form of diabetes is caused by a single mutation in a number of 
genes such as GK, HNF1-alpha, HNF4-alpha, IPF1 (Pdx1), KLF11 (Colom et al., 2010). 
2.3 Treatment 
Currently, there is no cure for diabetes. Secondary complications associated with the disease are 
of major concern. Unfortunately, existing therapies fail to provide adequate control over keeping 
blood glucose levels under control urging the need for a more effective and long-lasting treatment 
for diabetes (Halban et al., 2010). 
2.4 Self- Monitoring of Blood Glucose (SMBG)  
 
Self-monitoring of blood glucose (SMBG) did not become available until the 1940’s, until then 
blood glucose monitoring was an extensive laboratory process. The first self-assessment of blood 




until the 1970’s that self-monitoring of blood glucose was performed using reagent strips and a 
small drop of blood. This advancement in technology allowed hour to hour monitoring using a 
small volume of blood with only 10 % error. Drawbacks of this form of SMBG include: 
inconvenience, discomfort, secondary infections, repeated insulin injections and the risk of 
arriving at a hypoglycemic insult (Chee et al., 2004). With advancements in both research and 
technology, the development of the artificial pancreas began in 2003.  
 
2.5 Artificial Pancreas 
The artificial pancreas has been developed in an attempt to increase the quality of life for people 
who suffer from diabetes. This device mimics the function of a normal pancreas as it consists of 
an implanted glucose monitoring device that is continuously supplied by the venous blood flow 
from the patient (Chee et al., 2004; Halban et al., 2010). The inclusion of a small computer and 
pump allows this system not only to perform “real time” measurements of the blood glucose 
levels, but also provides the means to ensure the release of accurate amounts of insulin at any 
given point in time. The main advantage of this system is the fact that the artificial pancreas 
relieves the patient from the tedious self-monitoring task and it ensures a tight normal glycemic 
control. However, several drawbacks including the need of invasive subcutaneous implantation, 
continuous calibration of the glucose sensing module, the increased chance for infection, blood 
clot formation as well as the irritation originating from sensor insertion site are the major 
limitations for the widespread use of this technology (Chee et al., 2004; Halban et al., 2010).   
2.6 Islet Transplantation 
Islet transplantation is a strategy that aims to replenish the reduced β-cell mass in both MODY 
and type 1 diabetics by implanting islets from a deceased donor. Pancreatic islet transplantation 
became a successful method in the treatment of type 1 diabetes after the implementation of the 
Edmonton protocol, allowing a reduction in the number of islets that is required in the 




immunosuppression post transplantation (Bretzel, et al. 2007; Yones et al., 2008; Shapiro et al., 
2006; Shapiro et al., 2000). Nevertheless, the success of this method seems to be restrained by at 
least two major factors, including a limited islet supply and the need to use immunosuppressive 
drugs to ensure graft survival. It has been estimated that successful human islet transplantation 
requires at least 5000 islet equivalents per kilogram of body weight and can require up to three 
pancreatic donors, before the patient is no longer considered to be insulin-dependent (Shapiro et 
al., 2006; Yones et al., 2008). Although, the human islet isolation procedure has been 
standardized, islet yield continues to have a highly unpredictable and variable outcome 
(Kenmochi et al., 2008; Hara, et al., 2006; Yones et al., 2008; Halban et al., 2010).  
Transplantation experiments in animals have demonstrated that approximately 50 % of the 
transferred islets will not engraft, and the clinical outcome of the transplantation procedure is 
negatively affected by the loss of functional capacity of the transplanted islets due to stress from 
the isolation and culture procedure, local inflammatory processes and/or the occurrence of 
hypoxia before revascularization is achieved (Bretzel et al., 2007; Yones et al., 2008; Halban et 
al., 2010). This poor graft survival has urged the need for an immunosuppressive regimen in the 
transplantation strategy which also encompasses a number of disadvantages for the patient, such 
as an increased risk of malignancy or life threatening infections. It should be noted that the long-
term side effects of immunosuppressive medication are unknown. If the need for systemic 
immunosuppression could be significantly reduced, islet transplantation could be applied in the 
earliest stage of diabetes, during childhood. Several strategies, including gene therapy are 
currently being addressed in order to cope with the current limitations of islet transplantation and 









3.1 Viral gene-delivery  
 
The most common delivery system for gene therapy is viral-mediated-gene transfer. Viral vectors 
are favored as gene delivery vehicles due to their easy production; high functioning titers and 
their ability to infect many different cell types (Mayer et al., 2008; Robbins et al., 1998). The 
most frequently used virus for gene delivery is the Adenoviral derived viruses (Feril et al., 2005). 
Gene therapy using viral vectors is achieved by integrating a target DNA sequence into the 
viruses’ genome and exposing that virus to a target cell. The result is the desired gene integrated 
and expressed in a target cell (Roberts et al., 1998; Unger et al., 2001;). This form of gene 
therapy has been used for many treatments including cardiovascular disease of the myocardium 
and promotion of new blood vessels in ischemic tissue (Robbins et al., 1998; Unger et al., 2001;).   
 
Gene therapy using viral vectors has been approved in human clinical trials. In 1989, the first 
human clinical trial was performed using viral vectors as gene delivery agents to treat cancer by 
inserting a gene into immune cells (Roberts et al., 1998). After this success, over 300 human 
clinical trials have been performed using viral vectors as gene delivery vehicles to treat disease 
(Roberts et al., 1998). However, many drawbacks exist when using viral vectors as a vehicle for 
gene therapy, such as: cytotoxicity, physical changes to the target cells, mediated mutagenesis of 
genomic DNA, and most importantly the ability to elicit an immune response (Robbins et al., 
1998; Feril et al., 2005; Roberts et al., 1998). In 1995, a fatal accidental death occurred resulting 
from the use of adenoviral vectors for gene therapy through systemic administration. This death 
was the result of the over activation of innate immune system. This resulted in the re-evaluation 






3.1 Non-Viral Gene Delivery 
 
The strong inflammatory response initiated in vivo during gene delivery application using viral 
vectors has propelled research into the development of non-viral gene carriers who’s clinical 
application can be deemed safe. When developing a non-viral gene delivery system several 
aspects must be considered. The delivery system must be capable of repeated administration with 
little to no immune response, low cost, stable at non-extreme conditions and easily administered 
to patients (Davis, et al., 2002; Gary et al., 2007). A new class of gene delivery agents called 
cationic lipids have been synthesized for this purpose. 
 
3.2 Cationic Lipids 
 
Cationic lipids are positively charged phospholipids that readily bind and transfect DNA into a 
target cell. Two classes of cationic lipids exist, monovalent and a recently new family of cationic 
lipids called gemini surfactants. Structurally, cationic lipids are composed of a positively charged 
α-amino acid head group and a hydrophobic fatty acid tail (Figure 4). The positively charged 
amino group is attached to its hydrophobic region by a linker; an example of a linker is glycerol 
(Tors et al., 2010; Rao et al., 2010). Transfection capabilities of cationic lipids depend on several 
structural factors. Such factors include the combination of the cationic amino head group, degree 
of the hydrophobic tails and the bond that links the hydrophobic tails (Yingyongnarongkul et al 
2009; Rao et al., 2010). These structures can be very unstable; it is for this reasons that co-helper 
lipids are used. The most commonly used helper lipid is DOPE which helps structurally maintain 
the cationic lipid and increase transfection capabilities (Yingyongnarongkul et al 2009; Zhi et al., 


















Figure 4: Structure of a Monovalent Cationic Lipid
monovalent cationic lipid used to deliver plasmid DNA both 
mainly composed of hydrophobic and hydrophilic regions. The positively charged amino acid 
head group is attached by what is known as a linker; an example of a linker is glycerol. This 
linker is attached to a hydrocarbon chain of fatty acids. E
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The hydrophobic domains of cationic lipids are very important in the self assembly of liposomes 
or microbubbles in the presence of helper lipids (Tranchant, et al. 2004). Cationic lipids have the 
capabilities to form various structures when suspended in solution. Some of the most common 
structures include the multilamellar, hexagonal, inverted hexagonal phase and spherical or 
liposomal structures (Figure 5) (Ma et al 2007). These structures have the ability to form 
spontaneously in solution. The type of structure formed is dependent upon the conditions in 
which lipids are developed such as: temperature, pH, the presence of other ions, and the ratio of 
lipids to DNA (Caracciolo et. al., 2005; Ma et al. 2007; Zhdanov et al., 2002). These factors will 
control the shape of the lipoplex. Lipids have the capabilities to shape shift during changing 
conditions. Research presented by Caracciolo et al., (2005) indicated that DC-CHol/DOPE-DNA 
complexes form a lamellar phase at temperatures ranging from 0-4°C, and these complexes have 



























Figure 5: Structures Formed by 
four possible structures cationic lipids can form 
form a lipoplex, B) Inverted hexagonal lattice
or liposomal structure composed of an aqueous or gas filled center with DNA sandwiched 
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Cationic Lipids Suspended in Solution. Illustration
A) lamellar structure, cationic lipid and DNA 
, C) Intercalated hexagonal structure
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Nucleic acids and cationic lipids spontaneously interact through electrostatic interactions (Zuhorn 
et al. 2002; Zhdanov et al., 2002; Wasungu et al., 2006). It is the spontaneous interaction between 
DNA and cationic lipids which form what is known as a lipoplex. These interactions with 
cationic lipids depend on factors such as incubation time with DNA, cationic lipid to helper lipid 
concentrations, and lipid to DNA ratios. Ultimately, these factors will have major impacts on the 
shape a lipoplex will form (Ma et al 2007; Rao et al., 2010).  
 
Monovalent cationic lipids are the most commonly used, and have been shown to have high 
transfection capabilities; examples include Lipofectamine 2000, Fugene and DOTAP. Currently, 
more research has been focused on the design of cationic lipids in order to increase their DNA 
binding and transfection capabilities with reduced cellular toxicity. Recently, an extended amount 
of research has gone into the design of cationic lipids to increase DNA binding with superior 
surface binding capabilities, increased transfection, reduced toxicity, lower costs for economic 
advantages, and increased safety for in vivo application. A new family of cationic lipids called 
gemini surfactants have been created for these purposes (Kirby et al., 2003; Wettig, et al 2007; 
Wettig et al., 2008). 
 
3.3 Gemini Surfactants 
 
Gemini surfactants are considered to be a relatively new class of cationic molecules. The 
structure of a gemini surfactant differs from the monovalent cationic lipid by the addition of a 
rigid spacer group (Figure 6). This additional spacer group increases surface DNA binding and 
packing capabilities 1000 times compared to the single chain, single head group of the 
monovalent cationic lipids (Kirby et al. 2003; Wettig et al., 2007; Wettig et al., 2008; Luciani et 




surfactants reduce the amount of compound required for a successful transfection and increases 








































Figure 6: Structure of a Gemini Surfactant Cationic Lipid. Gemini surfactant cationic lipids 
differ from monovalent cationic lipids due to the addition of a ridged spacer group. The spacer 
group increases surface DNA association and packing capabilities. Examples of divalent cationic 














The composition of the spacer chosen during the synthesis of gemini surfactants will depend 
upon the therapeutic agent being delivered. Several studies have investigated the effects that 
spacer length has on DNA binding and cellular transfection. Two commonly used spacers are the 
N-CH3, also known as aza, and the N-H imino group (Wettig, et al., 2008; Luciani et al., 2007).  
 
Studies have shown that as the length of a spacer increases so does cellular transfection rates. 
However, as the length of the spacer group becomes too large cellular transfection will be 
reduced due to the instability of the structure (Wettig et al., 2007). It has been determined that the 
addition of an NH group within the spacer group will increase trasfection rates. A study presented 
by Wettig and collogues determined that gemini surfactants containing a spacer length of 7 with 
the addition of an NH group could bind the greatest amount of DNA and have the highest 
transfection efficiencies when compared to the other experimental groups (Figure 7) (Wettig, et 
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Figure 7: Chemical Structure of Gemini S
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urfactants Exhibiting Different Spacer Groups: 








3.4 Colloidal Stability Measured Though Zeta Potential 
 
When designing transfection reagents for gene carriers it is important to understand their 
interactions at the colloidal level. If a system is not stable at the particle level transfection rates 
will decrease. Particle size and charge play dual roles in the stability of a colloidal system.  
 
Zeta potential can be defined as the overall charge a particle holds in solution. For a stable 
colloidal system to be achieved, zeta potentials must reach + or – 30 mV. This value indicates 
whether or not there is enough electrostatic repulsion between particles to create a stable particle 
system (Alatorre-Meda et al., 2010).  
 
As particles acquire a more neutral charge in a system, they become more attracted to each other. 
This attraction of particles is known as flocculation. As particles begin to flocculate, they form 
large aggregates that begin to sediment out of the system. Colloidal stability in a particle system 
is of particular importance when developing lipid gene carriers for intravenous administration. 
Stable, highly charged small particles allows lung clearance during administration and prevents 
the of blockage of small arteries or veins which can cause ischemic tissue or even death while in 
circulation (Kirby et al, 2003; Zhdanov et al., 2002).  
 
3.5 Cationic Lipids for Drug and Gene Delivery 
 
The general mechanism of transfection using non-viral vectors is achieved though endocytosis of 
a target cell (Kheirolomoom, et al., 2007; Kirby et al., 2003). Compared to viral vectors, the 
delivery of genes and therapeutic agents using cationic lipids must overcome several cellular 
barriers to result in a successful transfection. A virus has evolved naturally over millions of years 
to associate with a cells surface and efficiently delivery its contents into a target cell with extreme 
success rates. Unfortunately, cationic lipids have not naturally evolved mechanisms to enter into 




successful in a target cell, the efficiency of transfection is highly dependent upon the lipid 
structure, DNA packing and size (Ma, et al 2007; Zhdanov et al., 2002; Alatorre-Meda et al., 
2010). The association of DNA to a cationic lipid is achieved through electrostatic forces (zeta 
potential). Once DNA has bound to the lipoplex it is crucial that the lipoplex still holds a positive 
charge since the cellular membrane charge of a target cell is negative (Ma, et al 2007).  
 
Successful in vivo delivery of a lipoplex into a target tissue or cell occurs through several stages. 
First, selected DNA for delivery must be appropriately bound and protected by the gene delivery 
agent or lipoplex (Kirby et al., 2003; Zhdanov et al., 2002; Alatorre-Meda et al., 2010). Second, 
the cargo bound to the lipoplex must be transported to the target tissues though IP injection or 
intravenous administration while maintaining colloidal stability (Kirby et al., 2003). Third, bound 
cargo must enter the cell though endocytosis which occurs though electrostatic interactions. 
Fourth, bound cargo to lipoplex is internalized forming an endosome in the cell where DNA must 
dissociate from the lipoplex appropriately before becoming degraded by the lowering endosomal 
pH (Kirby et al., 2003; Hoekstra et al., 2007). It is at this stage of transfection the addition of an 
NH group in gemini surfactants spacer group results in higher transfection rates (Ma et al., 2008; 
Wettig, et al 2007; Kirby et al., 2003). The NH group present in the spacer group of a gemini 
surfactant is exceedingly sensitive to pH changes and allows DNA dissociation readily, compared 
to other gemini surfactant spacer groups (Wettig et al., 2007; Luciani et al., 2007). Fifth, the 
dissociated DNA must be transported to the nucleus and become expressed. All stages of 
transfection using non-viral vectors have several intracellular obstacles to overcome and 
expression can be extremely dependent on structure, size of particle, charge, and stability of the 
lipoplex during the different stages of transfection (Ma et al 2007; Kirby et al., 2003; Zhdanov et 
al., 2002). These obstacles/barriers of gene delivery using non-viral gene carriers, have resulted 
in the development of strategies to increase transfection, particularly for their in vivo use. A novel 
gene delivery system called ultrasound targeted microbubble destruction (UTMD) has been 
designed to help overcome these cellular barriers improving transfection rates in vivo (Unger et 




3.6 Ultrasound Targeted Microbubble Destruction 
 
Ultrasound targeted microbubble destruction (UTMD) is a new gene delivery system developed 
to increase transfection rates of non-viral gene carriers for their in vivo use. UTMD has been 
designed to help overcome cellular barriers and the difficulties using non-viral vectors to improve 
successful plasmid DNA delivery. UTMD results in high organ specificity, low invasiveness and 
a decreased immune reaction using its cationic counterparts (Mayer et al., 2008; Christiansen et 
al., 2003; Davis et al., 2002). This system combines ultrasound and cationic lipid microbubbles 
for gene delivery (Unger et al., 2001; Ohlerth, et al., 2007; Mayer et al., 2008).  
 
3.7 Microbubbles  
 
Microbubbles are small gas-filled colloidal particles composed of either monovalent cationic 
lipids or protein-polymers, and can range in size from 1-8µm, depending on the target tissue 
involved (Thatte et al., 2005; Tinkov et al., 2008; Sek-Wen Hui et al., 2008). The core of a 
microbubble is displaced using stable heavy gasses; this allows stability during circulation, 
contrast for visual ultrasound, and explosive drug/gene delivery properties. Microbubbles can be 
loaded with drugs or DNA in many different ways: attachment to the membrane using 
electrostatic interaction, encapsulation, the use of a ligand, or the incorporation using multilayer 
microbubbles (Dijkmans et al., 2004). Until the 1990’s microbubbles were known as contrast 
agents and used for diagnostic purpose. Microbubble contrast agents were combined with 
ultrasound for right heart opacification and cardiac shunt diagnostics. When combined with low 
frequency ultrasound the gas filled core causes white reflections or contrast allowing their 
movement to be monitored while in circulation (Tinkov, et al. 2008; Linder et al., 2004; Yoon et 
al., 2010). However, the half life of diagnostic contrast agent microbubbles was limiting, only 
remaining stable in circulation for approximately five minutes, due to an unstable shell. 
Microbubble size limited their use to diagnostics and large organ perfusion. These microbubbles 





Second generation microbubbles were developed to overcome previous obstacles by increasing 
stability and reducing size, but a reduced half life was still limiting their use. Eventually, the core 
of second generation microbubbles, which consisted of room air, was replaced with a stable gas 
such as perfluorocarbons. Using a stable gas such as perfluorocarbons prolongs stability in 
circulation for greater than 15 minutes (Tinkov, et, al., 2008; Mayer, et al., 2008). These non-
viral stable colloidal particles are now being explored to be used as vehicles to deliver drugs or 
genes into a target tissue or cell in combination with high frequency ultrasound.  
 
3.8 UTMD Delivery Mechanism 
 
It is the incorporation of both ultrasound and microbubbles which make the UTMD system 
unique. High frequency ultrasound is used to destroy the gas-filled microbubbles, this not only 
guarantees the release of the cargo in the vicinity of the target cells, but also facilitates cargo 
uptake through the production of microjets from the exploding microbubbles (Pitt et al., 2004; 
Dijkmans et al., 2004; Unger et al., 2001; Meijering et al., 2009; Chen et al., 2006). When 
exposed to high frequency ultrasound, the gas present within the core of the microbubble to 
become highly compressed; this compression causes the microbubble to explode, releasing its 
contents at the target tissue. This mechanism of action is also known as cavitation (Figure 8) (Pitt 
et al., 2004). The collapse of the microbubbles from high frequency ultrasound creates high-
energy microstreams or microjets. These microjets cause stress to the surrounding cells, 
increasing their cellular membrane permeability (Unger et al., 2001; Dijkmans et al., 2004; 















Figure 8: Ultrasound Targeted Microbubble Destruction: 
ultrasound targeted microbubble destruction. Microbubbles attached with drugs or 
perfused through the circulation, targeted using ultrasound and destroyed with high frequency 



















The exact mechanism of cellular uptake of therapeutic agents into a cells’ cytosol using UTMD is 
not completely understood (Meijering et al., 2009). It has been recently suggested that one 
mechanism of cellular uptake using UTMD is induced by transient holes, or pores in the cellular 
membrane. In contrast, it is proposed that ultrasound causes small depressions rather than pores 
in the cellular membrane which induces endocytosis (Meijering et al., 2009; Chen et al., 2006).  
 
Several research groups have tried to investigate the exact mechanism of UTMD and how its 
action results in cellular transfection. Studies by Meijering and colleagues (2009) reported that 
cell cultures exposed to ultrasound causes pore formation in the plasma membrane. These pores 
result in the influx of Ca
2+
 inside the cell. This rise in calcium concentrations inside the cell 
results in the increased formation of hydrogen peroxide within the cells cytosol. This observation 
was also reported by the Jufferman’s group, where a significant increase in cytosolic hydrogen 
peroxide was observed after cells were exposed to ultrasound (Juffermans et al., 2006). This 
increase in hydrogen peroxide was associated with the influx of Ca
2+
 inside the cell due to 
cellular membrane permeability. The increase in hydrogen peroxide has a direct correlation to 
endocytosis (Meijering et al 2009).  
 
Endocytosis into a cell can occur through several different endocytotic pathways: clathrin-
mediated endocytosis, caveolin-mediated endocytosis and macropinocytosis (Meijering et al., 
2009). After the confirmation that ultrasound results in a Ca
2+
 influx into the cell, the Meijering 
group further investigated the process of endocytosis with UTMD by using individual blockers of 
the three main pathways of endocytosis. This research group was able to conclude that 
endocytosis and pore formation to deliver therapeutic compounds is dependent on molecular size 
of the drug/gene delivery agent (Meijering et al 2009). When all endocytotic pathways were 
blocked, the uptake of therapeutic agents was restricted, but only to molecules with a size greater 
than 500kDa. These results supported but did not completely explain the processes of UTMD 




play a duel role but the complete mechanism of this uptake is still not completely understood 
(Meijering et al 2009).  
 
3.9 UTMD and its In Vivo Application 
 
Several scientists have been successful in delivering genes into target tissues using monovalent 
constructed microbubbles with the UTMD system. Work presented by Shuyuan Chen has 
illustrated the success in using monovalent Lipofectamine 2000 microbubbles and UTMD in 
delivering a target gene into rat pancreatic islets. These scientists were successful in the targeting 
of a reporter gene into pancreatic islets by using the rat insulin 1 promoter (RIP) and successfully 
delivering a β-cell specific hexokinase I gene to increase insulin secretion using Lipofectamine 
2000 microbubbles (Chen et al., 2006). The scientists concluded that the use of monovalent 
Lipofectamine 2000 microbubbles with high frequency ultrasound resulted in the delivery of 
DNA with limited inflammatory response. Monovalent microbubbles loaded with plasmid DNA 
can be delivered into the circulation reducing invasive surgery, high organ specificity (with the 
use of ultrasound) resulting in no damage to pancreatic islets after microbubble infusion with 
ultrasound (Chen et al., 2006). Work presented by Bekeredjian, confirmed gene delivery of 
CMV-luciferase plasmids to the heart, achieving high transgene expression and high organ 
specificity four days after exposure also with the use of monovalent microbubbles (Bekeredjian et 
al., 2003). A third study presented by Bekeredjian also illustrated the successful use of UTMD in 
delivering plasmid DNA to the skeletal muscle of rats. High gene expression was shown seven 
days after administration of UTMD with the VEGF (vascular endothelial growth factor) gene. 
This study demonstrated that ultrasound combined with monovalent microbubbles is a safe 





3.10 UTMD as a tool for diabetes treatment 
UTMD-based gene delivery holds great promise for gene therapy as this method has overcome 
the difficulties and barriers that impeded the existing viral vector-based methods for successful 
clinical application (Unger et al., 2001; Bekeredjian et al., 2003; Yoon et al., 2010). UTMD has 
proven to be less immunogenic, less cytotoxic and more target specific than the viral vector based 
methods (Mayer et al., 2008; Bekeredijian et al., 2003). The target specificity of UTMD can even 
be increased by placing the gene of interest under a cell type-specific promoter, restricting its 
expression to certain cells in the targeted organ (Chen et al., 2006; Christiansen et al., 2003).  
The identification of genes involved in β-cell function, survival, growth and neogenesis, suggests 
that UTMD holds great potential in the treatment of diabetes as the restoration of β-cell mass 
and/or improvement of β-cell function would alleviate the metabolic burden in both type 1, 
MODY and type 2 diabetics (Stock et al., 2004).  
Recent work published by Dr. P.A. Grayburn focused on delivering the vascular endothelial 
growth factor (VEGF) gene to the liver using monovalent microbubbles incorporated with 
UTMD to promote islet revascularization post transplantation. Remarkably, the results 
demonstrated an increase in both vessel growth and density in transplanted islets, drastically 
improving their functionality post transplantation (Shimoda et al., 2010). A second study by Dr. 
P.A. Grayburn demonstrated the successes of monovalent microbubbles with the UTMD 
technique by delivering a series of genes to stimulate endocrine development. Six genes such as 
Pax4, NKx2.2, NKx6.1, Ngn3, Pdx and Mafa, were delivered into streptozotocin-induced 
diabetic rats and resulted in islet regeneration and restoration of both β-cell mass and normalized 
of blood glucose levels in the animal models (Chen et al., 2010).  
 
As clearly demonstrated, UTMD as a gene delivery system to treat disease, such as diabetes has 
considerable potential. Previous work has demonstrated and supported its success using 




cationic lipid microbubbles such as Lipofectamine 2000 are very expensive to produce, and the 
quantities required to bind sufficient amounts of DNA is quite high; limiting their clinical 
application. Gemini surfactants have been recognized for their increased DNA binding 
capabilities and transfection rates equal to monovalent lipids but for a fraction of the cost 
(Wettig, et al., 2007; Kirby et al., 2003).  Developing a cost efficient microbubble gene carrier to 
incorporate with ultrasound while acquiring equal transfection rates to monovalent microbubble, 




The purpose of this study is to develop an optimized microbubble gene carrier using a new family 
of cationic lipids known as gemini surfactants to incorporate with ultrasound, and compare 
transfection capabilities in vitro to commercially used monovalent cationic lipid microbubbles 
using the UTMD gene delivery technique.  The major objectives and aims are: 
 
Objective 1: Optimization of a Microbubble Gene Carrier 
 
 Aim 1: 
Assess size and charge of gemini surfactants 16-3-16 and 16-7NH-16 and compare to 
Lipofectamine 2000  
 
Hypothesis (1): Gemini surfactants would achieve a smaller particle size with increased 
charge based on the additional spacer group. 
 
Aim 2: 
Assess the effects of DNA binding on particle size and charge of gemini surfactants 16-3-





Hypothesis (2): A reduced particle size and reduced loss in surface charge would be 
achieved from gemini surfactant 16-7NH-16 after the addition of DNA due to the N-H 
imino group present within the spacer.  
 
 
Objective 2: In Vitro Assessment of Optimized Microbubble Gene Carrier 
 
Aim 4: Human Embryonic Kidney Cells – HEK 293 and Rat Insulinoma Cells – INS-1 
832/13 
Assess transfection efficiencies and toxicity effects of gemini surfactant microbubbles in 
vitro using HEK 293 and INS-1 832/13 cells. Compare transfection capabilities to 
monovalent cationic lipids  
 
Hypothesis (3): Gemini surfactant 16-7NH-16 microbubbles would exhibit higher transfection 
rates with reduced toxicity based on the increased DNA binding effects demonstrated by the N-H 
imino group reducing the amount of compound required for transfection, while maintaining a 
reduced particle size and increased surface charge.  
 
Objective 3: Assess UTMD DNA release 
 
(1) Assess pAMAXA plasmid GFP DNA binding and release using ultrasound on gemini 
surfactant microbubbles  
 
Hypothesis (4): Ultrasound exposure to gemini surfactant 16-7NH-16 microbubbles would 
release DNA cargo based on the explosion properties ultrasound exposure has on compressed 











Gemini surfactants 16-3-16 and 16-7NH-16 were synthesized and provided by Dr. Shawn Wettig 
from the University Of Waterloo School Of Pharmacy. Monovalent cationic lipids Lipofectamine 
2000, Fugene, DOTAP and neutral lipids DL-α-Phosphitdylcholine, Dipalmitolyl (DPPC) and L-
α-Phosphatidylethanolamine, dioleoly were purchased from Sigma. Plasmid Endofree Plasmid 
Giga kit was purchased from QIAGEN. Visual Sonics SoniGene 1 MHz probe, Visual Sonics 
Vevo System and wavelength clear ultrasound gel was purchased from visual sonics. The 
SoniGene 1MHz probe applies 1MHz of ultrasound to causes sonoporation and microbubble 
destruction to target cells at intensities that can range between 0.5 and 2.0 W/cm
2
. The Visual 
Sonics Vevo system is used to identify the region of interest and allow image-guided injection of 
microbubble gene carriers.  
 
Plasmid DNA Synthesis 
 
Plasmid pAMAXA GFP DNA plasmid was used that had a CMV driven promoter to express 
GFP. Plasmid DNA was propagated from Escherichia coli and purified using a QIAGEN 
EndoFree Plasmid Giga kit (12391) following the protocol provided by the manufacturer.  
 
Synthesis of Cationic Lipid Stocks 
 
Lipid stocks were prepared similar to the protocol developed by Chen (2007). 25 mg of neutral 
lipids DL-α-Phosphitdylcholine, Dipalmitolyl (DPPC) (Sigma P-5911), 2.5 mg of L-α-




was added to 1 mL of modified PBS (Hyclone), achieving a 2:1 molar ratio (neutral lipids to 
gemini surfactant). Lipid stock solutions were sonicated (Probe Sonicator Misonix Ultrasonic 
Liquid Processor XL-2000) for approximately 30 seconds at an output of 3 watts.  
 
Synthesis of Microbubbles 
 
Microbubble lipid solution was prepared as previously described (Chen 2007) by measuring out 
10 µl of glycerol (Sigma), 880 µl modified PBS, 60 µl Opti-MEM and 50 µl of premade lipid 
stock (see above). Microbubble lipid solutions were perfused with perfluorocarbon gas and 
vortexed for approximately 30 seconds.  
 
Displacement of the Aqueous Center 
 
Using a needle, neutral microbubble lipid solution was injected into clear wavelength ultrasound 
gel. Visual Sonics Vevo system was used to visually confirm the displacement of the aqueous 
center by identifying white contrast in ultrasound gel; and a SoniGene 1 MHz probe was applied 




Particle Size and Charge 
 
Microbubble lipid solution was used to measure microbubble size and charge. Microbubble 
particle size was measured in µm using dynamic light scattering on the Zetasizer (Nano ZS, 
Malvern). Microbubble particle charge was determined though electrophoresis and measured in 
mV by the Zetasizer (Nano ZS, Malvern), the same microbubble lipid solution was used to 








Gemini Surfactant pAMAXA Plasmid DNA Binding Analysis through Electrophoresis gel 
 
Neutral lipid and gemini surfactant 16-7NH-16 2:1 ratio microbubbles were prepared with the 
addition of 25 µg of plasmid pAMAXA GFP DNA. Microbubbles and pAMAXA plasmid DNA 
were loaded onto a 1% agarose gel.   
In Vitro Assessment of Optimized Microbubbles using UTMD 
 
HEK 293 cells and INS-1 832/13 were cultured in RPMI 1640 medium containing 10 % fetal calf 
serum, 10 mmol/l HEPES, 2 mmol/l L-glutamine, 1mmol/l Na-pyruvate, 50 µmol/l-
mercaptoethanol, 100 U/ml of penicillin, and 100 µg/ml streptomycin (Sigma) at 37 °C and 5% 
CO2. Both cell lines were added to a 12 well plate at densities of 0.75 x10
6
 cells per well. Cells 
were left to adhere to culture plate 24 hours or kept in suspension. Four microbubble solutions 
were tested in cell culture using ultrasound 1) Lipofectamine 2000, following manufactures 
protocol, 2) Fugene, following manufactures protocol 3) DOTAP, following manufactures 
protocol 4) Gemini surfactant 16-7NH-16. 25 µg of plasmid pAMAXA GFP DNA was 
additionally added to all microbubble solutions. SoniGene 1 MHz ultrasound probe was used and 




 and 2.0 W/cm
2
. Cellular transfection rates 
were determined though visual estimation of the percentage of cells expressing GFP using 
fluorescent microscopy. Cell viability was assessed by the number of cells not adhered to culture 
plate after transfection, this determined the death rate after transfection. 
 
Plasmid DNA Binding and Release using UTMD 
 
Neutral and gemini surfactant 16-7NH-16 microbubbles 2:1 and 10:1 ratio were prepared with 
the addition of 50 µg of plasmid pAMAXA GFP DNA. A SoniGene 1 MHz probe was is applied 









The research in this study focused on developing a gemini surfactant microbubble capable of 
gene delivery into HEK 293 and INS-1/13 cells using high frequency ultrasound. This was 
achieved through detailed investigation of two cationic gemini surfactants 16-3-16 and 16-7NH-
16 as possible microbubble gene carriers. These surfactants microbubbles were compared to 
commercially used monovalent microbubbles Lipofectamine 2000, Fugene and DOTAP for 
transfection capabilities. Particle size, zeta potential, colloidal stability and DNA binding was 
heavily assessed. 
 
5.2 Optimization of a Microbubble Gene Carrier 
 
Assessing Gemini Surfactant Particle Size 
 
Assessing gemini surfactant particle size and comparing to monovalent Lipofectamine 2000 
would give a good indication as to whether these surfactants would be suited for gene delivery in 
vivo for intravenous administration and cellular uptake. It was hypothesized that both gemini 
surfactant microbubbles would achieve a smaller particle size based on the addition of the spacer 
group. Particle size of cationic microbubbles containing gemini surfactants 16-3-16, 16-7NH-16, 
and Lipofectamine 2000 was investigated using dynamic light scattering and compared to neutral 
lipid microbubbles (negative control). Figure 9 illustrates microbubble particle size among each 
group. Smallest microbubble particle size was achieved from both gemini surfactant 16-3-16 at 
0.167 µm and 16-7NH-16 at 0.275 µm when compared to Lipofectamine 2000 at 3.09 µm and 








Figure 9: Particle size comparison of cationic gemini surfactants 16-3-16, 16-7NH-16, and 
Lipofectamine 2000 Microbubbles: Three experimental groups were compared to control 
microbubbles (neutral lipid MB, made with DPPC and DOPE). 1) Gemini surfactant 16-3-16 at a 
2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant MB, 2) Gemini surfactant 16-7NH-16 
at a 2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant MB, 3) Lipofectamine 2000 MB. 
Particle size was measured using the dynamic light scattering on a Malvern Zetasizer Nano ZS. 
The error bars represent the difference between particle size measurements, n=1 and 
measurements were taken three times at the particles surface using dynamic light scattering. 
Smallest particle size was achieved by both gemini surfactants 16-3-16 at 0.167 µm and 16-7NH-
























Particle Surface Charge Analysis through Zeta Potential 
 
Particle surface charge was compared to Lipofectamine 2000. Determining a particles surface 
charge confirms not only colloidal stability but also DNA binding potential. Particle charge was 
determined though electrophoresis using a Zetasizer (Malvern Nano ZS). Figure 10 illustrates the 
zeta potential achieved from microbubble gemini surfactants 16-3-16, 16-7NH-16, Lipofectamine 
2000 MB and compared to neutral lipid microbubbles (negative control). Gemini surfactant 
microbubble particle charge was the highest detected among each group measuring 
+
29 mV for 
surfactant 16-3-16 and 
+
30 for surfactant 16-7NH-16. The zeta potential detected by both gemini 
surfactant microbubbles exhibited little difference, with an average surface charge of 
approximately 
+
30 mV. Lipofectamine 2000 MB measured 
-
6.2 mV and 
+
9.8 mV for neutral lipid 
























Figure 10: Zeta potential comparison of cationic gemini surfactants 16-3-16, 16-7NH-16, and 
Lipofectamine 2000 Microbubbles: Three experimental groups were compared to control 
microbubbles (neutral lipid MB, made with DPPC and DOPE).  1) Gemini surfactant 16-3-16 at a 
2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant MB, 2) Gemini surfactant 16-7NH-16 
at a 2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant MB, and 3) Lipofectamine 2000 
MB. Zeta potential is determined by electrophoresis on the Malvern Zetasizer Nano ZS and is 
measured in mV. Measurements were taken at the particles surface and a charge determined. The 
error bars represent the difference between charge measurements, n=1 and measurements were 
taken three times using electrophoresis. Gemini surfactant 16-3-16 measured a surface charge of 
+
29 mV  and 16-7NH-16 
+
30 mV indicating a stable colloidal system when compared to 
Lipofectamine 2000 MB measuring 
-
6.2 and neutral lipids DPPC and DOPE MB at 
+







Plasmid pAMAXA GFP DNA binding effects on particle size 
 
Determining DNA binding and its effects on particle size of non-viral gene carriers is a critical 
phase to investigate, considering in vivo application. Figure 12 represents the results of the 
addition of 50 µg of plasmid pAMAXA GFP DNA and the effects on microbubble particle size. 
The results indicate the addition of plasmid pAMAXA GFP DNA increases microbubble particle 
size. Gemini surfactant 16-3-16 particle size increased from 0.167 µm to 2.23 µm after the 
addition of pAMAXA GFP DNA. Gemini surfactant 16-7NH-16 increased in particle size from 
0.275 µm to 0.74 µm after the addition of pAMAXA GFP DNA. Gemini surfactant microbubbles 
16-3-16 exhibited the largest increase in particle size when compared to surfactant 16-7NH-16 

























Figure 11: Particle size comparison of cationic gemini surfactants with and without the 
addition of plasmid pAMAXA GFP DNA: Graph illustrating the average particle size of 
gemini surfactants 16-3-16 and 16-7NH-16 MB with and without the addition of plasmid 
pAMAXA GFP DNA. Two experimental groups were examined 1) Gemini surfactant 16-3-16 at 
a 2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant with and without the addition of 50 
µg of DNA, 2) Gemini surfactant 16-7NH-16 at a 2:1 ratio of neutral lipids (DPPC and DOPE) to 
surfactant MB with and without the addition of 50 µg of DNA. Particle size increases with the 
addition of 50 µg of plasmid pAMAXA GFP DNA in both surfactants. Particle size was 
measured using the dynamic light scattering on a Malvern Zetasizer Nano ZS. The error bars 
represent the difference between particle size measurements, n=1 and measurements were taken 
three times at the particles surface using dynamic light scattering. Smallest particle size with the 
addition of 50 µg of DNA was achieved by gemini surfactant 16-7NH-16 increasing from 0.275 






 Plasmid pAMAXA GFP DNA binding effects on zeta potential 
 
The stability of a colloidal system can be changed or become lost with the addition of other 
cations or anions. Figure 13 illustrates the effect 50 µg of plasmid pAMAXA GFP DNA had on 
zeta potential of both gemini surfactant microbubbles. The addition of pAMAXA plasmid GFP 
DNA increased the zeta potential of both gemini surfactant microbubbles. Gemini surfactant 16-
3-16 increased in surface charge from 
+
34 mV to 
+
39 mV after the addition of pAMAXA GFP 
DNA, and surfactant 16-7NH-16 increased from 
+
34.6 mV to 
+
37.74 mV after the addition of 
pAMAXA GFP DNA.  These results demonstrate the direct influence the addition of DNA has 

























Figure 12: Zeta potential comparison of gemini surfactants 16-3-16 and 16-7NH-16 with and 
without the addition of plasmid pAMAXA GFP DNA: Graph illustrating the average zeta 
potential achieved by experimental groups 1) Gemini surfactant 16-3-16 at a 2:1 ratio of neutral 
lipids (DPPC and DOPE) to surfactant with and without the addition of 50 µg of DNA, 2) Gemini 
surfactant 16-7NH-16 at a 2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant MB with 
and without the addition of 50 µg of DNA. Zeta potential is determined by electrophoresis on the 
Zetasizer (Malvern Nano ZS) and is measured in mV. Measurements were taken at the particles 
surface and a charge determined. The error bars represent the difference between charge 
measurements, n=1 and measurements were taken three times using electrophoresis. Particle 
charge increases with the addition of 50 µg of plasmid pAMAXA GFP DNA. Gemini surfactant 
16-3-16 increased in surface charge from 
+
34 mV to 
+
39 mV and gemini surfactant 16-7NH-16 
from 
+
34.6 mV to 
+






Plasmid pAMAXA GFP DNA binding analysis of gemini surfactant 16-7NH-16 through gel 
electrophoresis 
 
Determining DNA binding and condensing properties of a non-viral gene carrier gives insight 
into maximum binding potential and confirms DNA interaction. Gemini surfactant 16-7NH-16 
was chosen for further investigation though gel electrophoresis due to higher DNA condensing 
properties (Wettig, et al., 2007). Figure 14 illustrates the binding capabilities of gemini surfactant 
16-7NH-16 microbubbles with the addition of 25 µg of plasmid pAMAXA GFP DNA using gel 
electrophoresis analysis. Gemini surfactant 16-7NH-16 MB was compared to pure 25 µg plasmid 
pAMAXA GFP DNA and neutral lipid microbubbles with the addition of 25 µg of plasmid 
pAMAXA GFP DNA as controls. A DNA incubation time line was performed to determine if an 
incubation period is required to bind plasmid pAMAXA GFP DNA to gemini surfactant 16-7NH-
16. The results confirm no pre-incubation period is required to fully bind and condense 25 µg 
plasmid pAMAXA GFP DNA to gemini surfactant 16-7NH-16 microbubbles. This interaction 





















Figure 13: Gemini surfactant plasmid DNA binding analysis through gel electrophoresis: 
Gel electrophoresis image illustrating plasmid pAMAXA GFP DNA binding of gemini surfactant 
16-7NH-16 MB. A time line of 15 and 30 minutes of incubation with plasmid pAMAXA GFP 
DNA was examined.  Lanes 1, 2 and 3 were incubated with plasmid pAMAXA GFP DNA for 15 
minutes. Lanes 4, 5 and 6 were incubated with pAMAXA GFP DNA for 30 minutes. 
µg plasmid pAMAXA GFP DNA (positive control), 
and DOPE)  + 25 µg plasmid pAMAXA GFP DNA (negative control), 
16-7NH-16 at a 2:1 ratio of neutral lipids (DPPC and DOPE) to surfactant MB + 
plasmid pAMAXA GFP DNA. Lane
charged lipid MB (DPPC and DOPE), Lane 6









Lane 2) Neutrally charged lipid MB (DPP
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 4) 25 µg plasmid pAMAXA GFP DNA, Lane 
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5.3 In Vitro Assessment of Optimized Microbubble Gene Carrier 
 
 Assessing ultrasound transfection capabilities in attached HEK 293 cells  
Investigating and optimizing ultrasound transfection capabilities in vitro not only confirm the 
efficiency of ultrasound as a gene delivery system, but also provide useful information to test 
once this gene delivery system in an in vivo model. Figure 16 represents the results of the 
investigation; assessing ultrasound effects on cellular transfection in attached HEK 293 cells with 
gemini surfactant 16-7NH-16 microbubbles. Gemini surfactant microbubbles were synthesized 
and compared to controls, 1) Neutrally charged MB + 25 µg plasmid pAMAXA GFP DNA 
(negative control), 2) Monovalent cationic lipid Fugene + 25 µg plasmid pAMAXA GFP DNA 
(positive control), and 4) 25 µg plasmid pAMAXA GFP DNA (negative control). After 48 hours 
cells were accessed for GFP expression. Cellular transfection rates were determined by visually 
estimating the percentage of cells expressing GFP using fluorescent microscopy after exposure to 
ultrasound (see figure legend for details). Positive control group Fugene + 25 µg of plasmid 
pAMAXA GFP DNA demonstrated positive expression of GFP with transfection rates at 100 %. 
Negative control group neutrally charged MB exhibited a 15 % transfection rate, followed by a 
15 % transfection rate from negative control 25 µg plasmid pAMAXA GFP DNA at ultrasound 
intensity 2.0 W/cm
2
. Gemini surfactant 16-7NH-16 MB established a zero percent transfection 













Figure 14: Transfection efficiency comparison of pAMAXA plasmid GFP in attached HEK 
293 cells using ultrasound: After 48 hours of incubation, cells were assessed for GFP 
expression. Positive control Fugene + 25 µg of plasmid pAMAXA GFP DNA, negative control 
neutral lipid microbubbles 10:1 ratio (DPPC:DOPE) + 25 µg of plasmid pAMAXA GFP DNA 
and 25 µg plasmid pAMAXA GFP DNA were compared to experimental group gemini surfactant 
16-7NH-16 2:1 ratio (DPPC:DOPE:16-7NH-16) + 25 µg of plasmid pAMAXA GFP DNA. n = 3 
for each group. Using a SoniGene 1 MHz probe, microbubbles were destroyed in cell culture 













Assessing ultrasound cell viability after transfection in attached HEK 293 cells  
 
Figure 17 illustrates the estimated percent cell viability in transfected HEK 293 cells using 
ultrasound. After 48 hours cells were assess for viability. These results indicate gemini surfactant 
16-7NH-16 MB + 25 µg plasmid pAMAXA GFP DNA with the incorporation of the ultrasound 
technique results in high cell death rates. The most prevalent percent cell death rate was achieved 
from gemini surfactant 16-7NH-16 MB + 25 µg plasmid pAMAXA GFP DNA at a ultrasound 
intensity 1.0 W/cm
2
, reaching death rates of 90 %. As ultrasound intensities decreased, gemini 
surfactant 16-7NH-16 MB demonstrated a drop in percent cellular death to approximately 45 % 




 and including 
control. Cell death rate, on average, was low for both negative control group’s neutrally charged 
MB + 25 µg plasmid pAMAXA GFP DNA and 25 µg plasmid pAMAXA GFP DNA with cell 
death rates less than 5 %. Zero percent cell death was observed from Fugene + 25 µg plasmid 
























Figure 15: Cell viability of transfected HEK 293 cells using ultrasound: After 48 hours cell 
viability was assessed. Positive control Fugene + 25 µg of plasmid pAMAXA GFP DNA, 
Negative control neutral lipid microbubbles 10:1 ratio (DPPC:DOPE) + 25 µg of plasmid 
pAMAXA GFP DNA and 25 µg plasmid pAMAXA GFP DNA were compared to experimental 
group tested gemini surfactant 16-7NH-16 2:1 ratio (DPPC:DOPE:16-7NH-16) + 25 µg of 
plasmid pAMAXA GFP DNA. n = 3 for each group. Using a SoniGene 1 MHz probe 














 Assessing ultrasound transfection capabilities in suspended HEK 293 cells  
 
Figure 18 illustrates cellular transfection of HEK 293 cells in suspension with gemini surfactant 
16-7NH-16 microbubbles incorporated with ultrasound. The parameters of this investigation 
were modified to cells in suspension due to the lack of transfection expressed by cells attached to 
culture plate. Experimental groups investigated remained the same as previously investigated 
except for the addition of two experimental groups, neutral lipids + DOTAP MB + 25 µg plasmid 
pAMAXA GFP DNA  and 25 µg plasmid pAMAXA GFP DNA + DOTAP MB. These two 
experimental groups were added for comparative purposes to gemini surfactant 16-7NH-16 MB + 
25 µg plasmid pAMAXA GFP DNA and are commercially used monovalent cationic lipids. 
After 48 hours of incubation cells were collected and counted for GFP expression. The results of 
this investigation illustrated the highest percent transfection was observed from positive control 
group Fugene + 25 µg plasmid pAMAXA GFP DNA, with a 70 % transfection rate while not 
exposed to ultrasound. Experimental group 25 µg plasmid pAMAXA GFP DNA + DOTAP MB 
illustrated transfection rates at 30 % and remained consistent between all ultrasound intensities, 
including control, not exposed to ultrasound. Experimental group neutral lipids + DOTAP MB + 
25 µg plasmid pAMAXA GFP DNA exhibited transfection rates which varied among ultrasound 
intensities; the highest transfection rate was observed from ultrasound intensity 2.0 W/cm
2 
with a 
30 % transfection rate. Gemini surfactant 16-7NH-16 MB + 25 µg plasmid pAMAXA GFP DNA 
demonstrated a 5 % transfection rate among all ultrasound intensities tested and a zero 
transfection rate in control. Neutrally charged MB (negative control) demonstrated an increase in 
transfection rates with increasing ultrasound intensities; highest transfection rate was observed at 
intensity 2.0 W/cm
2 













Figure 16: Transfection efficiency comparison of pAMAXA plasmid GFP in suspended HEK 
293 cells using ultrasound: After 48 hours of incubation, cells were assessed for GFP 
expression. Positive control Fugene + 25 µg of plasmid pAMAXA GFP DNA, Negative control 
neutral lipid microbubbles 10:1 ratio (DPPC:DOPE) + 25 µg of plasmid pAMAXA GFP DNA, 
25 µg plasmid pAMAXA GFP DNA and 25 µg plasmid pAMAXA GFP DNA + DOTAP were 
compared to experimental groups tested gemini surfactant 16-7NH-16 2:1 ratio 
(DPPC:DOPE:16-7NH-16) + 25 µg of plasmid pAMAXA GFP DNA and neutrally charged lipid 
microbubbles 10:1 ratio (DPPC:DOPE) + DOTAP + 25 µg of plasmid pAMAXA GFP DNA  n = 
3 for each group. Using a SoniGene 1 MHz probe microbubbles were destroyed in cell culture 














Assessing ultrasound cell viability after transfection in suspended HEK 293 cells  
Figure 19 illustrates the estimated percent cell viability in transfected HEK 293 cells in 
suspension with ultrasound. The results indicate the highest percent cell death rate observed from 
experimental group 25 µg plasmid pAMAXA GFP DNA + DOTAP MB (commercially used 
monovalent cationic lipid) with a percent death rate of approximately 90 %. This high cell death 
percentage was observed and maintained equally at all ultrasound intensities investigated, 
indicating ultrasound did not influence transfection rates from this experimental group. 
Experimental group 25 µg plasmid pAMAXA GFP DNA (negative control) reached cell death 
rates equal to 25 µg plasmid pAMAXA GFP DNA + DOTAP MB (90 %), although was only 
observed at ultrasound intensity 2.0 W/cm
2 
and was not evident at any other ultrasound 
intensities. Neutral lipids + DOTAP MB + 25 µg plasmid pAMAXA GFP DNA (commercially 
used monovalent cationic lipid) also exhibited high cell death rates reaching 90 % at ultrasound 
intensities 1.5 W/cm
2
 and 2.0 W/cm
2
, indicating ultrasound influenced cell death with increasing 
intensities. Gemini surfactant 16-7NH-16 MB + 25 µg plasmid pAMAXA GFP cell death rates 
was lower (68 %) when compared to commercially used monovalent cationic lipid DOTAP, 
ultrasound intensities influenced cell death rate with increasing ultrasound intensities from 1.0 
W/cm
2
 to 2.0 W/cm
2
, indicating the direct influence ultrasound had on cell death from this 
experimental group. Negative control group, neutrally charged MB, demonstrated comparable 
cellular death rates as gemini surfactant 16-7NH-16 MB + 25 µg plasmid pAMAXA GFP DNA 
with increasing ultrasound intensities. The lowest percent cell death was observed from positive 
control group Fugene (commercially used monovalent cationic lipid) with cell death rates as low 
















Figure 17: Cell viability of transfected HEK 293 cells in suspension using ultrasound: After 
48 hours cell viability was assessed. Positive control Fugene + 25 µg of plasmid pAMAXA GFP 
DNA, Negative control neutral lipid microbubbles 10:1 ratio (DPPC:DOPE) + 25 µg of plasmid 
pAMAXA GFP DNA, 25 µg plasmid pAMAXA GFP DNA and 25 µg plasmid pAMAXA GFP 
DNA + DOTAP were compared to experimental groups tested gemini surfactant 16-7NH-16 2:1 
ratio (DPPC:DOPE:16-7NH-16) + 25 µg of plasmid pAMAXA GFP DNA and neutrally charged 
lipid microbubbles 10:1 ratio (DPPC:DOPE) + DOTAP + 25 µg of plasmid pAMAXA GFP 
DNA  n = 3 for each group. Using a SoniGene 1 MHz probe microbubbles were destroyed in cell 













 Assessing ultrasound transfection capabilities of INS-1 832/13 cells in suspension 
 
A second cell line, INS-1 832/13, was used to test the transfection capabilities of gemini 
surfactant 16-7NH-16 incorporated with ultrasound. Figure 20 illustrates the results of cellular 
transfection of INS-1 832/13 cells with the incorporation of the ultrasound technique. The results 
indicated a zero transfection rate from all experimental groups tested. A minor transfection rate 
was indicated by negative control, neutrally charged MB + 25 µg plasmid pAMAXA GFP DNA, 
at an intensity of 2.0 W/cm
2
 with a 1 % transfection rate. Control groups not exposed to 
ultrasound demonstrated transfection rates of 40 % for both Lipofectamine 2000 MB + 25 µg 
plasmid pAMAXA GFP DNA and 25 µg plasmid pAMAXA GFP DNA. Gemini surfactant 16-
7NH-16 MB + 25 µg plasmid pAMAXA GFP DNA demonstrated a zero transfection rate at all 
























Figure 18: Transfection efficiency comparison of pAMAXA plasmid GFP in suspended INS-
1 832/13 cells using ultrasound: After 48 hours cells assessed for GFP expression. Positive 
control Lipofectamine 2000 + 25 µg of plasmid pAMAXA GFP DNA, Negative control neutral 
lipid microbubbles 10:1 ratio (DPPC:DOPE) + 25 µg of plasmid pAMAXA GFP DNA and 25 µg 
plasmid pAMAXA GFP DNA were compared to experimental group tested gemini surfactant 16-
7NH-16 2:1 ratio (DPPC:DOPE:16-7NH-16) + 25 µg of plasmid pAMAXA GFP DNA. n = 3 for 
each group. Using a SoniGene 1 MHz probe microbubbles were destroyed in cell culture 














Assessing ultrasound cell viability after transfection in suspended INS-1 832/13 cells 
 
Figure 21 illustrates estimated cell viability in transfected INS-1 832/13 cells using ultrasound. 
The results indicate the highest percent cell death rate observed from experimental group gemini 
surfactant 16-7NH-16 MB + 25 µg plasmid pAMAXA GFP DNA at a 90 % death rate, and was 
visible at all ultrasound intensities, including control group. All other experimental groups tested 
demonstrated little to no cellular death at all ultrasound intensities explored, except experimental 
group 25 µg plasmid pAMAXA GFP DNA. Death rate was directly impacted by the increase in 
ultrasound intensities. As ultrasound intensities increased from 1.0 W/cm
2
 to 2.0 W/cm
2
 cellular 
death rates also increased; indicating the impact ultrasound exposure intensities has on cell death. 
Experimental group neutrally charged MB + 25 µg plasmid pAMAXA GFP DNA (negative 
control) indicated a 1 % cell death rate at ultrasound intensity 2.0 W/cm
2
 and not seen at any 
other ultrasound intensities. Positive control, Lipofectamine 2000 MB + 25 µg resulted in a 5 % 























Figure 19: Cell viability of transfected INS-1 832/13 cells in suspension using ultrasound: 
After 48 hours cells were assessed for viability. Positive control Lipofectamine 2000 + 25 µg of 
plasmid pAMAXA GFP DNA, Negative control neutral lipid microbubbles 10:1 ratio 
(DPPC:DOPE) + 25 µg of plasmid pAMAXA GFP DNA and 25 µg plasmid pAMAXA GFP 
DNA were compared to experimental group tested gemini surfactant 16-7NH-16 2:1 ratio 
(DPPC:DOPE:16-7NH-16) + 25 µg of plasmid pAMAXA GFP DNA. n = 3 for each group. 
Using a SoniGene 1 MHz probe microbubbles were destroyed in cell culture solution. Ultrasound 














Assessing plasmid pAMAXA GFP DNA binding and release using ultrasound 
 
To achieve successful gene delivery using ultrasound, the cargo loaded onto the non-viral gene 
carrier must be released once exposed to ultrasound. Figure 15 A illustrates the results of the 
ultrasound release of 50 µg of plasmid pAMAXA GFP DNA from gemini surfactant 16-7NH-16 
MB. Plasmid pAMAXA GFP DNA release was compared to 1) 50 µg plasmid pAMAXA GFP 
DNA (negative control), and 2) neutral lipid MB + 50 µg of plasmid pAMAXA GFP DNA 
(negative control). For comparative purposes, the first experimental group was synthesized and 
not exposed to ultrasound and seen in Figure 15 A lanes 4, 5, and 6. A second sample group was 
tested for plasmid pAMAXA GFP DNA release by ultrasound exposure. Lipid solutions were 
exposed to ultrasound for 30 seconds then loaded onto electrophoresis gel. The results indicate no 
difference between experimental groups exposed and not exposed to ultrasound with respect to 
plasmid pAMAXA GFP DNA release. Another experimental group was tested and is represented 
in Figure 15 B, using gemini surfactant 16-7NH-16 MB at a 10:1. Figure 15 B indicates a 
reduced binding capability of gemini surfactant 16-7NH-16 MB at a 10:1 rather than 2:1 ratio in 
both ultrasound exposed and not exposed groups. This was indicated by the small amount of 
plasmid DNA detected on the agarose gel. These results confirm ultrasound has no release effect 















Figure 20: Plasmid pAMAXA GFP DNA binding and r
condensing and release using ultrasound 
control 50 µg pAMAXA GFP DNA,
DPPC: DOPE + 50 µg pAMAXA GFP DNA. 
2:1 ratio (DPPC:DOPE:16-7NH
pAMAXA plasmid GFP DNA were 
seconds then loaded onto a 1 % aragrose gel. Figure 
gel electrophoresis. Control groups used remained the same, experimental group gemini 
surfactant 16-7NH-16 was reduced to a 10:1 ratio 
50 µg pAMAXA GFP DNA. All experimental parameters stayed the same as seen in figure 
60 
elease with ultrasound
assessed by gel electrophoresis. Figure 
 negative control neutral lipid microbubbles 10:1 ratio 
Experimental group gemini surfactant 16
-16) + 50 µg pAMAXA GFP DNA. Microbubbles
exposed to ultrasound with a 1MHz SoniGene probe for 30 
B) DNA condensing and release assessed by 











Displacement of the Aqueous Center   
 
Displacement of the aqueous center is desired for efficient gene delivery when incorporated with 
ultrasound. The investigation into the displacement of the aqueous center of synthesized 
microbubbles suggests the methodology used to synthesize microbubbles is successful in 
achieving a gas filled center. Figure 11 illustrates the displacement of the aqueous center of 
neutrally charged microbubbles. Microbubbles were successfully targeted and destroyed using 



























Figure 21: Ultrasound Mediated
Destruction of neutral gas filled microbubbles with the 1MHz 
and visualized using the Visual Sonics 
synthesized and injected into ultrasound gel using a 16 G needle (white streaks indicated by 
arrow). The microbubbles appear white
waves. Ultrasound waves cannot pass though air, resulting in their refection seen on the 
ultrasound image. B) Microbubbles were destroyed using pulse Visual Sonics SoniGene 1 MHz 
probe. This resulted in the destruction of the bubbles under the high frequency ultrasound 






 Destruction of Neutral Gas Filled Microbubbles: 
high frequency ultrasound
Vevo system. A) Neutral gas filled microbubbles were 









The purpose of this study was to develop an optimized microbubble gene carrier using a new 
family of cationic lipids known as gemini surfactants to incorporate with the ultrasound delivery 
technique. Gemini surfactants have been recognized for their superior DNA binding capabilities, 
colloidal stability, increased transfection rates and for their economic advantages (Kirby et al., 
2003; Wettig et al., 2007). Developing an optimized microbubble gene carrier using gemini 
surfactants to be incorporated with ultrasound would ultimately increase success rates for its in 
vivo and clinical application. 
 
The first objective of this study was to assess microbubble particle size and charge (zeta 
potential) of gemini surfactants 16-3-16, 16-7NH-16 and compare them to monovalent cationic 
lipid Lipofectamine 2000. Investigating and determining particle size is important because 
administration of non-viral microbubble gene carries is performed intravenously; these particles 
must acquire a small size while suspended in solution to allow lung clearance during circulation, 
safety without causing death by restricting small arterioles or blood vessels and requires total 
perfusion into a target tissue for in vivo application (Tinkov et al., 2008; Yoon et al., 2010; Kwon 
et al., 2008). Also, gene delivery into a target cell using ultrasound is thought to be induced by 
endocytosis. As a particle comes into contact with a cell’s surface it facilitates endocytosis (Kirby 
et al., 2003; Zhdanov et al., 2001). This pathway can be restricted by large particles resulting in 
decreased transfection rates (Meijering et al., 2009). Assessing charge of a particle system 
provides information on the particles dispersion, colloidal stability, biological characteristics and 
drug/gene loading capacities (Tinkov et al., 2008). An increased surface charge results in longer 
capillary retention times while in circulation after intravenous administration. The attachment of 
drugs or genes onto a non-viral gene carrier is achieved though surface electrostatic interaction. 




for efficient DNA binding (Ma et al., 2007; Zhdanov et al., 2002; Gary et al., 2007; Alatorre-
Meda et al., 2010). Predetermining size and charge of cationic particles prior to DNA loading 
gives insight for their use as non-viral gene carriers. Particle size and charge play dual roles in 
creating a stable non-viral gene delivery system. 
 
When assessing particle size of gemini surfactant species 16-3-16 and 16-7NH-16 both 
surfactants achieved a smaller and more desirable particle size of 0.167 µm for 16-3-16 and 0.275 
µm for surfactant 16-7NH-16 when compared to Lipofectamine 2000 (3.09 µm) prior to DNA 
loading. Gemini surfactants achieved a size between 1-8µm, which is safe for intravenous 
administration, organ perfusion and for facilitated cellular uptake (Thatte et al., 2005; Meijering 
et al., 2009). Particle surface charge, measured though zeta potential, revealed both gemini 
surfactants achieving a strong surface charge of 
+
29 mV for gemini surfactant 16-3-16 and 
+
30 
mV for gemini surfactant 16-7NH-16 when compared to Lipofectamine 2000 (-6.2 mV). These 
values indicate that gemini surfactants achieved a greater stable colloidal system with quality 
dispersion properties, enough electrostatic repulsion between particles for intravenous 
administration for increased retention times, and sufficient DNA binding potential when 
compared to Lipofectamine 2000, where size and charge indicates an unsafe and unstable 
colloidal system.  
 
It was hypothesized that gemini surfactants would achieve a smaller particle size with increased 
charge based on the additional spacer group. These results support this hypothesis since both 
gemini surfactants achieved a smaller particle size with increased surface charge when compared 
to the monovalent cationic lipid Lipofectamine 2000.  
 
What makes gemini surfactants so unique compared to monovalent cationic lipids is the addition 
of a spacer group. This ridged spacer adds an additional amino group to be incorporated into its 
structure, providing an increased positive surface charge (Kirby et al., 2003; Wettig et al., 2007).  




suggested that the additional amino group not only increases a particles surface charge but also 
causes these particles to compact into smaller structures due to the flexibility of the spacer group 
as repulsion between particles is high. The results support both the hypothesis and previous 
literature of gemini surfactants’ small size and superior surface charge due to the additional 
spacer group when compared to monovalent cationic lipid microbubbles (Wettig et al., 2003, 
Ewert et al, 2002). 
 
The second objective of this study was to assess the effects DNA binding has on particle size and 
charge of gemini surfactants 16-3-16 and 16-7NH-16. Lipofectamine 2000 was no longer 
compared for DNA binding assessment due to the information provided by the results based on 
an increased particle size and reduced surface charge prior to DNA assessment. It is important to 
assess the effects DNA binding has on particles’ size and charge to ensure DNA is interacting at 
the particles’ surface for efficient gene delivery; and appropriate microbubble size parameters are 
being maintained for intravenous administration, a suitable size for cellular uptake, while still 
maintaining colloidal stability. The results of this investigation demonstrate that gemini 
surfactant 16-3-16 increased in particle size after the addition of DNA from 0.167 µm to 2.23 µm 
and gemini surfactant 16-7NH-16 increased in particle size from 0.275 µm to 0.73 µm. Particle 
surface charge, measured though zeta potential after the addition of DNA demonstrated that both 
gemini surfactant 16-3-16 and 16-7NH-16 increased in surface charge. Surfactant 16-3-16 
increased from 
+
34 mV to 
+







It was hypothesized that a reduced particle size and reduced loss in surface charge would be 
achieved from gemini surfactants 16-7NH-16 after the addition of DNA due to the N-H imino 
group present within the spacer. These results support this hypothesis and gemini surfactant 16-
7NH-16 achieved a reduced particle size while maintaining a high surface charge when compared 





DNA binding and condensing properties of gemini surfactants are directly correlated to spacer 
composition (Kirby et al., 2003). Two commonly used spacers groups, the aza and imino groups 
were investigated for their DNA binding potential and compacting capabilities. Previous studies 
have revealed that gemini surfactants which contain an N-H group have a strong DNA binding 
capacity, increased DNA binding affinity, and condensing and compaction properties (Wettig et 
al.,  2007; Luciani et al., 2007). The imino group differs from the aza by an additional amino 
group present within the spacer. This results in an additional DNA binding site and increased 
surface charge. It can be concluded from these results that the additional N-H group present in the 
spacer allowed greater DNA condensing resulting in the reduced particle size of gemini 
surfactant 16-7NH-16. The additional imino N-H group present within the spacer can also 
influence charge. Prior to the addition of DNA, gemini surfactant 16-7NH-16 achieved a greater 
surface charge.  Although after the addition of DNA both particle systems exhibited in a shift in a 
positive charge, to approximately 
+
38 mV. This shift in charge can be typical of a highly charge 
particle system. Literature has supported that as DNA interacts with the cationic compound, the 
negative charge can be reduced, diminished or even shift to a positive charge as the negative 
charge of DNA is neutralized by the positive charge of the liposome (Alatorre-Meda et al., 2010; 
Felgner et al., 1995). This coincides with the results in the increased positive surface charge 
observed by both gemini surfactants. These results indicated that gemini surfactant 16-7NH-16 
achieved a smaller particle size after the addition of DNA maintaining appropriate parameters for 
intravenous administration, cellular uptake, while maintaining a strong surface charge. This 
investigation determined that DNA is affecting the particle system but does not confirm DNA 
surface binding. Further investigation was done using gel electrophoresis to determine surface 
interaction. Due to the superior surface compacting capabilities demonstrated by gemini 
surfactant 16-7NH-16 it was chosen for further surface DNA binding investigation.  
 
The results in figure 14 confirm plasmid DNA surface binding to gemini surfactant 16-7NH-16 
microbubbles. Gemini surfactant 16-7NH-16 was able to fully bind, and quenched plasmid DNA 




fluorescent tag that binds to nucleic acids and is commonly used for gel electrophoresis. 
Surfactant 16-7NH-16 microbubbles were able to bind and condense DNA to such capacities that 
ethidium bromide was not able to penetrate or bind to the nucleic acids present on plasmid DNA. 
This investigation supports the strong binding and compacting capabilities of surfactant 16-7NH-
16 which contains the N-H imino spacer group. 
 
The third objective of this study was to assess transfection efficiencies and toxicity rates in vitro 
of gemini surfactant 16-7NH-16 microbubbles and to compare monovalent microbubbles with 
the incorporation of ultrasound. The importance of this investigation was to determine whether or 
not synthesized gemini surfactant 16-7NH-16 microbubbles can in fact transfect DNA at equal or 
higher rates with reduced toxicity into two cell lines with the incorporation of ultrasound to be 
used as non-viral microbubble gene carriers.  
 
The results of the in vitro assessment revealed that gemini surfactant 16-7NH-16 microbubbles 
cannot transfect DNA at either equal or higher rates with reduced toxicity when compared to 
monovalent cationic microbubbles. Transfection rates of gemini surfactant 16-7NH-16 
microbubbles in HEK 293 cells demonstrated a 5 % transfection rate with approximately a 68 to 
90 % death rate. When compared to the monovalent cationic microbubbles, both Fugene and 
DOTAP exhibited the highest transfection rates between 100 % (Fugene) and 30 % (DOTAP) 
with the lowest death rate observed from Fugene at 0 %. DOTAP demonstrated a 90 % death rate 
when incorporated with ultrasound. When assessing transfection rates of gemini surfactant 16-
7NH-16 microbubbles in INS-1 832/13 cells a 0 % transfection was observed and a 90 % death 
rate. This was compared to monovalent Lipofectamine 2000 microbubbles which exhibited a 40 
% transfection rate and a 5 % death rate overall.  
 
It was hypothesized that gemini surfactant 16-7NH-16 microbubbles would exhibit higher 
transfection rates with reduced toxicity based on its reduced particle size, colloidal stability, 




N-H imino group. The results of this investigation did not support the hypothesis, despite the 
encouraging results presented by surfactant 16-7NH-16 during the previous investigations. 
Overall, monovalent cationic lipid microbubbles demonstrated not only higher transfection rates, 
but also exhibited lower toxicity rates when compared to gemini surfactant 16-7NH-16.  
 
The lack of transfection observed by gemini surfactant 16-7NH-16 microbubbles coincides with 
the high toxicity rates observed in both cell lines. There are several possible reasons for the lack 
of transfection such as cytotoxicity and exposure to high frequency ultrasound. Ultrasound is 
known to enhance transfection rates by facilitating the uptake of particles into a target cell 
(Meijering et al., 2009; Unger et al., 2001; Pitt et al., 2004). It has been established that the 
uptake of large quantities of cationic lipids can result in cell death due to toxicity (Ewert, et al., 
2002). It is plausible that the highly charged gemini surfactants together with ultrasound resulted 
in an increased particle uptake causing toxicity to the cells. Ultrasound frequencies used in this 
investigation were heavily increased for in vitro use. Several studies have used reduced 
ultrasound frequencies when delivering plasmid GFP to culture cells (Wang et al., 2008; Zhou et 
al., 2009). Reducing the surfactant to neural lipid ratio, and ultrasound frequencies could reduce 
cellular death rates and increase cellular transfection. Literature has shown support to increasing 
transfection rates with more neutral particles by increasing the addition of neutral lipids (co-
helper lipids) to cationic lipids resulting in lower toxicity and increased transfection rates (Gary 
et al., 2007; Ewert, et al., 2002; Borden et al., 2005; Alatorre-Meda, et al., 2010). This can be a 
contradictory concept considering the theory behind DNA binding, complexing with lipid 
structures and cellular membrane charge. Much research has been dedicated to understanding 
how these complexes work and understanding the structure they form when complexed with 
DNA. Research has indicated that the amount of neutral lipid applied to the molar ratio will affect 
the structure a lipoplex will form as well as transfection rates (Alatorre-Meda et al., 2010). One 
study investigated transfection efficiencies when changing the mass ratio of cationic lipids to 
neutral. This study observed a dramatic increase in transfection efficiencies as the amount of 




2002; Alatorre–Meda, et al., 2010). This drastic increase in transfection rates as neutral lipids are 
increased is particularly evident when using multivalent cationic lipids (Ewert, et al., 2002; Zhi et 
al., 2010). Further investigation must be done to confirm whether or not gemini surfactants can 
deliver nucleic acid for gene therapy efficiently when incorporated with ultrasound. This study 
did not fully explore all the experimental possibilities during the transfection process using 
ultrasound. Although it was previously determined that monovalent cationic lipid microbubbles 
demonstrated large particle size and reduced charge indicating an unstable system, our in vitro 
assessment determined monovalent cationic lipid microbubbles are more efficient gene carriers 
when incorporated with the ultrasound technique. 
 
The lack of transfection observed from gemini surfactant 16-7NH-16 microbubbles was 
confusing despite the encouraging results presented and supported by each hypothesis. Gene 
delivery using the ultrasound technique does require the release of its cargo from the cationic 
lipid to be transfection and expressed within the cell. It is plausible that perhaps the lack of 
transfection observed from gemini surfactant 16-7NH-16 was a result of the DNA not released 
from the lipid during ultrasound exposure. Previous investigations determined that DNA was 
interacting with the gemini surfactant microbubble surface after DNA addition by increasing in 
particle size, increasing surface charge, and confirmation though gel electrophoresis. It can 
therefore be hypothesized that a reduction in transfection rates will be observed from transfection 
reagents who’s cargo cannot be released during ultrasound exposure.  
 
The results seen in figure 21 confirm gemini surfactant 16-7NH-16 was unable to release DNA 
after ultrasound exposure and support this hypothesis. Gemini surfactant 16-7NH-16 
microbubbles were synthesized at a 2:1 ratio and were chosen for investigation based the results 
of previous investigations demonstrating a small particle size, increase surface charge and DNA 
binding capabilities. These results suggest that the 2:1 ratio used might bind plasmid DNA with 
such strong forces that ultrasound may not be able to successfully release plasmid DNA from its 




may be so strong that DNA cannot be released during the appropriate stage, resulting in low 
levels of gene expression (Gary, et al., 2007). Neutral lipid microbubbles have a reduced ability 
to bind DNA (Figure 14). It is predicted that an increase in the amount of neutral lipids could 
reduce the DNA binding and condensing capabilities of surfactant 16-7NH-16 microbubbles to 
help facilitate the release with the incorporation of ultrasound, resulting in higher transfection 
rates in vitro. Although, not included in the study objectives, and after the observation of DNA 
not released from gemini surfactant 16-7NH-16 microbubbles, it was suggested that perhaps the 
aqueous center of synthesized microbubbles was not being displaced by the perfluocarbone gas. 
To confirm the methodology used to displace the aqueous center of synthesized gemini surfactant 
microbubbles both visual and high frequency ultrasound were used to confirm methodology. 
Gene delivery using ultrasound requires a gas filled microbubble center for microbubble 
explosion to deliver its contents (Thatte et al., 2005; Tinkov et al., 2008; Unger et al., 2002, 
Djkmans et al., 2004). It is hypothesized that obtaining a microbubble gas filled center and when 
exposed to high frequency ultrasound will result in its destruction. It is important to ensure the 
methodology used for microbubble synthesis is correct in achieving the acquired conditions to be 
incorporated with ultrasound for efficient gene delivery using this technique.  
 
The results seen in figure 11 confirm and support the hypothesis that a gas filled microbubble 
center is achieved and is destroyed when exposed to high frequency ultrasound. Therefore with 
respect to the lack of transfection observed by gemini surfactant 16-7NH-16 in vitro, this was not 
due to the methodology used in achieving a gas filled center. It must be stated that only neutral 
lipids were used to confirm this methodology. Since gemini surfactants were not used to confirm 
a gas filled center it cannot be fully concluded that synthesized gemini surfactant microbubbles 
were actually achieving the required conditions, however, the methodology used does generate 









The costs of monovalent cationic lipids are quite high, resulting in economic drain for their 
clinical use. Gemini surfactants would be an ideal transfection reagent to be used when 
incorporated with the UTMD technique for treatment based on their low cost and the reduced 
amount of surfactant compound required to bind DNA. This is quite attractive for their in vivo 
use by increasing safety during application and their economic advantages. Further detailed 
investigation and studies are required to determine if gemini surfactants could be incorporated 
with the UTMD technique. Ideally, low cost, easy production, high transfection capabilities, lack 
of immunogenicity, low toxicity are the most sought out principles when developing non-viral 
gene carriers. Cationic lipids for gene delivery have been taken to the stage of clinical trials, 
although the efficiency of synthetic vectors still needs to be greatly improved as demonstrated 
during the investigation of this study. With the increasing success using UTMD as a gene 
delivery system, UTMD holds great promise as a potential gene delivery system to improve the 
treatment of islet transplantation. More sufficient investigation and optimization is required, 
although its potential holds great promise to treat disease. 
 
Conclusion 
In conclusion to this study, it was determined through detailed investigation that the most 
appropriate microbubble gene carries to be incorporated with ultrasound for gene delivery for in 
vitro cell culture are the monovalent cationic lipids. This is the first investigation known to use 
gemini surfactants to synthesize microbubble gene carriers and incorporate them using this 
technique. Unfortunately, in vitro assessment of the investigation of gemini surfactants illustrated 
negative results reducing their use as microbubble gene carriers to be incorporated with the 









Gene therapy holds great promise to treat a variety of human diseases, including diabetes. 
Diabetes is a devastating disease affecting millions of people worldwide, ultimately reducing the 
quality of life. Current treatments are available to help alleviate this burden but the quality of life 
for diabetics is still compromised. Diabetics are continuously faced with an uphill battle and 
constant reminders of future secondary complications which can impede their life and in some 
cases leading to premature death. The development of the artificial pancreas is a fast developing 
alternative treatment, although many drawbacks still impede its progression and diabetics are 
burdened by surgical implantation and the carrying an insulin pump at all times. Ultimately, islet 
transplantation is the ideal form of treatment for diabetics. This form of treatment alleviates 
diabetics from constant self-monitoring and carrying devices upon which they are dependent. 
Islet transplantation as a form of treatment for diabetes would allow diabetics to live an insulin 
independent life without the burden of secondary complications. The success of the “Edmonton 
Protocol” catapulted research into a possible cure (Bretzel et al., 2007; Shapior et al., 2006; 
Yones et al., 2008; Halban et al., 2010). Although, limitations such as islet supply, survival and 
immunosuppression impede its progression. The characterization of genes that either enhance β-
cell functionality, islet revascularization or increase β-cell mass either through controlled 
proliferation, transdifferentiation or neogenesis, holds great promise for the application of gene 
therapy as a treatment for diabetes. Initial experiments with viral vectors have highlighted the 
shortcoming of this strategy. The cytotoxic and immunogenic nature of the viral gene carriers has 
urged the need to develop a more effective non-viral gene delivery method, such as UTMD. The 
organ-specific application of a ultrasound pulse, which not only initiates cargo release, but also 
facilitates the cargo uptake by the target cells, indicates that UTMD is particularly well suited for 
the pancreatic delivery of a combination of genes that will increase functional β-cell mass and the 
revascularization post islet transplantation (Chen et al., 2010; Shimoda et al., 2010). Further and 
future investigation into designing a more cost efficient microbubble gene carrier to be 
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